KARYOTYPE AT DIAGNOSIS, SUBSEQUENT LEUKEMIC TRANSFORMATION AND SURVIVAL IN MYELODYSPLASTIC SYNDROME

被引:7
|
作者
MUSILOVA, J
MICHALOVA, K
ZEMANOVA, Z
NEUWIRTHOVA, R
DOHNALOVA, A
CIESLAR
CMUNT
CERMAK
HABER
KLAMOVA
LEMEZ
LUKASOVA
SISKOVA
TRNENY
机构
[1] CHARLES UNIV,MED FAC & HOSP 1,DEPT CLIN HEMATOL,CR-112821 PRAGUE 2,CZECH REPUBLIC
[2] CHARLES UNIV,FAC MED 1,DEPT BIOSTAT,CR-112821 PRAGUE 2,CZECH REPUBLIC
关键词
CHROMOSOMES; MYELODYSPLASTIC SYNDROME; ACUTE MYELOID LEUKEMIA; PROGNOSTIC SCORE;
D O I
10.1016/0145-2126(94)00131-S
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
240 patients with MDS studied cytogenetically at diagnosis between 1981 and 1990 were followed until death or until April 1992 to evaluate the prognostic significance of FAB classification, age and karyotype. 61 patients (25.4%) subsequently transformed into AML and 176 (73.3%) died during the follow-up period. Patients with blastic MDS types had a shorter survival and a higher probability of leukemic transformation. The younger age increased the probability of leukemic transformation, but was associated with a longer survival. The absence of analyzable mitoses was associated with a shorter survival. The complex chromosomal abnormalities at the initial evaluation identified a subgroup of patients with a high risk of a short survival and/or subsequent leukemic transformation. In refractory anemia the presence of complex chromosomal abnormalities was linked with a relative risk of 3.58 of leukemic transformation and shorter survival as compared with other cytogenetically defined groups.
引用
下载
收藏
页码:303 / 308
页数:6
相关论文
共 50 条
  • [21] MYELODYSPLASTIC SYNDROMES - INCIDENCE AND RISK FOR LEUKEMIC TRANSFORMATION
    JAKAB, I
    PECZE, K
    FODOR, F
    BLUT, 1988, 56 (06): : C11 - C11
  • [22] When karyotype is decisive for myelodysplastic syndromes diagnosis
    Borgo, Aline dos Santos Perazzio
    Chauffaille, Maria de Lourdes L. Ferrari
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2019, 41 (04) : 371 - 373
  • [23] Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome
    Slape, Christopher I.
    Saw, Jesslyn
    Jowett, Jeremy B. M.
    Aplan, Peter D.
    Strasser, Andreas
    Jane, Stephen M.
    Curtis, David J.
    BLOOD, 2012, 120 (12) : 2475 - 2483
  • [24] A MYELODYSPLASTIC SYNDROME WITH LEUKEMIC TRANSFORMATION DIAGNOSED WITH LUMBAR PUNCTION AFTER BREAST CANCER TREATMENT
    Taktakoglu, O.
    Sumbul, H.
    Balli, O.
    Guven, B.
    Sahin, B.
    LEUKEMIA RESEARCH, 2014, 38 : S60 - S60
  • [25] Evaluation of complex karyotype in a patient with myelodysplastic syndrome
    Ilgin-Ruhi, Hatice
    Vicdan, Arzu
    Ozen, Mehmet
    Ilhan, Osman
    Gurman, Gunhan
    CHROMOSOME RESEARCH, 2013, 21 : S102 - S102
  • [26] DETECTION OF LATENT KARYOTYPE ABNORMALITIES IN MYELODYSPLASTIC SYNDROME
    Kokhno, A. V.
    Pimenova, M. A.
    Parovichnikova, E. N.
    Domracheva, E. V.
    Savchenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2014, 59 (01): : 25 - 28
  • [27] Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation
    Ohyashiki, K
    Iwama, H
    Yahata, N
    Tauchi, T
    Kawakubo, K
    Shimamoto, T
    Ohyashiki, JH
    LEUKEMIA & LYMPHOMA, 2001, 42 (03) : 291 - 299
  • [28] p53 protein as useful immunohistochemical marker for predicting leukemic transformation of the myelodysplastic syndrome
    Horvath, E.
    Dorcioman, B.
    Molnar, E.
    Demian, S.
    Turcu, M. L.
    Chira, L.
    Nagy, E. E.
    Finna, C.
    VIRCHOWS ARCHIV, 2015, 467 : S198 - S198
  • [29] ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome
    Wang, Hong
    Wang, Xiao-Qin
    Xu, Xiao-Ping
    Lin, Guo-Wei
    LEUKEMIA RESEARCH, 2010, 34 (05) : 598 - 604
  • [30] SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome
    Ma, Yan
    Song, Jing
    Chen, Bobin
    Xu, Xiaoping
    Lin, Guowei
    ONCOTARGET, 2016, 7 (06) : 6566 - 6575